Comparative Pharmacology
Head-to-head clinical analysis: BUTENAFINE HYDROCHLORIDE versus NYSTATIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTENAFINE HYDROCHLORIDE versus NYSTATIN.
BUTENAFINE HYDROCHLORIDE vs NYSTATIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits squalene epoxidase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Nystatin binds to sterols in the fungal cell membrane, primarily ergosterol, altering membrane permeability and causing leakage of intracellular components, leading to fungal cell death.
1% cream applied topically once daily for 2 weeks for tinea pedis, 1 week for tinea corporis/cruris.
Oral: 500,000 to 1,000,000 units (5-10 mL suspension) swish and swallow 3-4 times daily; Vaginal: 1 vaginal tablet (100,000 units) once or twice daily; Topical: Apply cream/ointment 2-3 times daily; duration depends on indication.
None Documented
None Documented
Clinical Note
moderateNystatin + Tranilast
"The risk or severity of adverse effects can be increased when Nystatin is combined with Tranilast."
Clinical Note
moderateNystatin + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Nystatin is combined with Tolfenamic acid."
Clinical Note
moderateNystatin + Nimesulide
"The risk or severity of adverse effects can be increased when Nystatin is combined with Nimesulide."
Clinical Note
moderateNystatin + Risedronic acid
Terminal elimination half-life is approximately 35–40 hours following topical application; long half-life supports once-daily dosing.
Due to minimal systemic absorption, a terminal elimination half-life is not clinically relevant. In vitro plasma degradation half-life is approximately 1.5 hours, but this is not applicable in vivo.
Primarily metabolized in the liver; minimal excretion of unchanged drug. Less than 5% of a topical dose is absorbed systemically; excreted in urine and feces as metabolites.
Nystatin is not absorbed from the gastrointestinal tract after oral administration; virtually 100% of the ingested dose is excreted unchanged in the feces. After topical application, systemic absorption is negligible; any absorbed drug is excreted via bile and feces (<1% renal).
Category C
Category A/B
Antifungal
Antifungal
"The risk or severity of adverse effects can be increased when Nystatin is combined with Risedronic acid."